Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22689 | 0.82 | — | — | |
| Water SCHEMBL31614340 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL6043 | 0.73 | — | — | |
| SCHEMBL29195976 | 0.73 | — | — | |
| Water SCHEMBL3800295 | 0.73 | — | — | |
| Water SCHEMBL25354626 | 0.73 | — | — | |
| Ammonia Solution, Strong SCHEMBL2749074 | 0.73 | — | — | |
| Phosphine SCHEMBL5852309 | 0.73 | — | — | |
| Water SCHEMBL28489054 | 0.73 | — | — | |
| SCHEMBL10935463 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3974273-A | AEROBICALLY CULTURING STREPTOMYCES | THE KITASATO INSTITUTE (JA) | 1976-08-10 | — | — | US | claimed |
| US-6576241-B2 | Extract from a plant crude drug, having given amount of soluble silicon compound calculated as silicon per gram of dry weight, and extract that inhibits production of plasma kallikrein; standardization | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| US-6541041-B1 | Quality of crude drug extracts containing soluble silicon compounds can be standardized using the soluble silicon compounds as an index; compounds exhibit inhibitory action towards the production of plasma kallikrein | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020006444-A1 | CRUDE DRUG EXTRACTS, AND METHODS FOR MAKING AND STANDARDIZING SAME | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| CN-1220164-A | Extracts from crude drugs | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1999-06-23 | — | — | CN | disclosed |
| EP-0919238-A2 | Crude drug extract containing soluble silicon | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-02 | — | — | EP | disclosed |
| US-3974273-A | AEROBICALLY CULTURING STREPTOMYCES | THE KITASATO INSTITUTE (JA) | 1976-08-10 | — | — | US | disclosed |